Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lewis Nasr

Showing results (11-20 of 17) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 17 results.
Journal of Hematology & Oncology|May 14, 2025
Molecular characterization and predictors of relapse in patients with Ph + ALL after frontline ponatinib and blinatumomabNicholas J Short, Hagop Kantarjian, Ken Furudate, et al.
Clinics and Research in Hepatology and Gastroenterology|July 15, 2024
Liquid biopsy as a tool for KRAS/NRAS/BRAF baseline testing in metastatic colorectal cancerHampig Raphael Kourie, Joseph Zouein, Ziad Zalaquett, et al.
Cancer|April 9, 2024
Combination of dasatinib and venetoclax in newly diagnosed chronic phase chronic myeloid leukemiaElias Jabbour, Fadi G Haddad, Koji Sasaki, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 19, 2024
Results of the Simultaneous Combination of Ponatinib and Blinatumomab in Philadelphia Chromosome-Positive ALLHagop Kantarjian, Nicholas J Short, Fadi G Haddad, et al.
Advances in Radiation Oncology|November 11, 2024
Ultra-Low-Dose Radiation for Extranodal Marginal Zone Lymphoma of the LungSusan Y Wu, Penny Q Fang, Ahmed Fetooh, et al.
Blood Advances|January 11, 2024
A phase 1/2 study of mini-hyper-CVD plus venetoclax in patients with relapsed/refractory acute lymphoblastic leukemiaNicholas J Short, Elias Jabbour, Nitin Jain, et al.
Journal of Hematology & Oncology|July 8, 2023
A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agentsNicholas J Short, Muharrem Muftuoglu, Faustine Ong, et al.
Pageof 2

Showing results (11-20 of 17) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
Journal of Hematology & Oncology|May 14, 2025
Molecular characterization and predictors of relapse in patients with Ph + ALL after frontline ponatinib and blinatumomabNicholas J Short, Hagop Kantarjian, Ken Furudate, et al.
Clinics and Research in Hepatology and Gastroenterology|July 15, 2024
Liquid biopsy as a tool for KRAS/NRAS/BRAF baseline testing in metastatic colorectal cancerHampig Raphael Kourie, Joseph Zouein, Ziad Zalaquett, et al.
Cancer|April 9, 2024
Combination of dasatinib and venetoclax in newly diagnosed chronic phase chronic myeloid leukemiaElias Jabbour, Fadi G Haddad, Koji Sasaki, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 19, 2024
Results of the Simultaneous Combination of Ponatinib and Blinatumomab in Philadelphia Chromosome-Positive ALLHagop Kantarjian, Nicholas J Short, Fadi G Haddad, et al.
Advances in Radiation Oncology|November 11, 2024
Ultra-Low-Dose Radiation for Extranodal Marginal Zone Lymphoma of the LungSusan Y Wu, Penny Q Fang, Ahmed Fetooh, et al.
Blood Advances|January 11, 2024
A phase 1/2 study of mini-hyper-CVD plus venetoclax in patients with relapsed/refractory acute lymphoblastic leukemiaNicholas J Short, Elias Jabbour, Nitin Jain, et al.
Journal of Hematology & Oncology|July 8, 2023
A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agentsNicholas J Short, Muharrem Muftuoglu, Faustine Ong, et al.
Pageof 2